Transplantační medicína

Tıpta yaşanan gelişmeler sonucunda artık yağ dokusu veya herhangi bir yerden alınan kök hücrelerinden insülin salgılayan hücre oluşturulup büyütülebiliyor. Bu da diyabet yönetiminde kök hücre dönemini beraberinde getiriyor.

Low platelet counts are one facet of ITP, but when we look at it from another angle, we see the multiple dimensions of ITP. ITP is a condition of complex immune dysregulation that reduces platelet counts—causing bleeding, bruising, fatigue, and other health-related quality-of-life (HRQoL) issues—while increasing inflammation and the risk of thromboembolic events (TEs).^1-5

Patients reported significant quality of life (QoL) challenges related to their ITP¹

For ITP patients, several scales are available to measure and track fatigue and its impact on quality of life. These tools can help patients and healthcare providers gauge symptoms and adjust their ITP treatment accordingly.^1-4

Complex immune dysregulation can lead to autoimmunity and inflammation^1-6

Farmakolojik gelişmelerin ötesinde, diyabet yönetiminde yapay zeka teknolojilerinin entegrasyonu sayesinde önemli bir dönüşüme tanıklık ediyoruz.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.